Clinical Trials
2 trialsNCT02900716 2020-11-27
Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Zhejiang DTRM Biopharma
Phase 1 Completed
NCT02891590 2020-04-14
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
Zhejiang DTRM Biopharma
Phase 1 Completed